


PHARMACEUTICAL 2022



Regulus Therapeutics Inc. Rank 196 of 466





PHARMACEUTICAL 2022





The relative strengths and weaknesses of Regulus Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Regulus Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 67% points. The greatest weakness of Regulus Therapeutics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 163%, being 85% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	65,235
Cost of Goods Sold	0
Intangible Assets	83
Liabilities, Current	5,227
Liabilities, Non-Current	8,269
Other Assets	3,136
Other Compr. Net Income	0
Other Expenses	856
Other Liabilities	0
Other Net Income	0
Other Revenues	864
Property and Equipment	0
Research and Development	17,794
Selling, General and Administrative Expense	10,022

Output Variable	Value in 1000 USD
Assets	68,454
Liabilities	13,496
Expenses	28,672
Revenues	864
Stockholders Equity	54,958
Net Income	-27,808
Comprehensive Net Income	-27,808
Economic Capital Ratio	163%

